Compare BioNano Genomics Inc (BNGO) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Live Nation Entertainment, Inc. — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Live Nation Entertainment, Inc. trades at $183.14 (market cap $42.71B). The key difference: Live Nation Entertainment, Inc. is far larger — about 3126.6× BioNano Genomics Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | LYV | |
|---|---|---|
Market Cap | $13.66M | $42.71B |
Sector | Health | Industrials |
52-Week High | $4.92 | $186.59 |
52-Week Low | $1.06 | $125.61 |
Enterprise Value | $16.26M | $44.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Live Nation (LYV) trades at $185.71, up 0.58% with strong bullish technical signals from moving averages. The stock shows mixed fundamentals with a high P/E of 117.49 but beat Q2 2026 earnings expectations. Revenue growth remains robust at $25.2B in 2025, though net margins are thin at 0.51%. Recent insider sales and legal concerns create headwinds despite analyst optimism.
Outlook remains cautiously optimistic with 87% analyst buy ratings and a $209.54 price target suggesting 13% upside. Key risks include elevated valuation, debt levels, and regulatory scrutiny. The company's dominant live events position and strong demand provide growth catalysts, but execution on cost management will be critical for profitability improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
